Associated tags: FDA, Acetylcholine receptor, GMG, Alfa Romeo, Patient, IIP, Euronext, Pharmaceutical industry
Locations: CHINA, JAPAN, NORTH AMERICA, NEW YORK, LONDON, NY, UK, BOSTON, DENMARK, GERMANY, BREDA, NL, SC, UNITED KINGDOM, DM, MG, SWITZERLAND, SAUDI ARABIA, CANADA, EUROPE, AUSTRALIA, NETHERLANDS, TD, MA
Vaccine,
Infection,
Abstract,
US Food Sovereignty Alliance,
Qualitative research,
Urinary tract infection,
Rash,
Efgartigimod alfa,
Tell,
Chills,
SC,
Wheeze,
GMG,
Food,
Fever,
AAN,
Efficacy,
Urination,
Chest pain,
American Academy,
Antibody,
Autoimmunity,
Cough,
Trial of the century,
Pain,
Administration,
Vitamin,
Respiratory tract infection,
Back pain,
Euronext,
MSE,
Risk,
Swelling,
ADAPT,
Immune system,
Immunoglobulin G,
Alfa Romeo,
Phlegm,
Immunization,
System,
Headache,
Neonatal Fc receptor,
Sore throat,
Skin,
Safety,
Fatigue,
Pharmaceutical industry,
Nursing,
Tolerability,
Patient The presentations include clinical and real-world efgartigimod data that demonstrate the potential of neonatal Fc receptor (FcRn) blockade in transforming treatment for gMG and other IgG-mediated autoimmune diseases.
Key Points:
- The presentations include clinical and real-world efgartigimod data that demonstrate the potential of neonatal Fc receptor (FcRn) blockade in transforming treatment for gMG and other IgG-mediated autoimmune diseases.
- Long-term treatment, administered in individualized dosing cycles, led to consistent and repeatable reductions in IgG antibody levels and improved clinical outcomes.
- A cross-indication review of the safety profile of efgartigimod will also be presented across multiple IgG-mediated autoimmune diseases, reinforcing the consistent safety profile observed with efgartigimod.
- Your health care provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART.
Cancer,
Inflammation,
Antibody,
Autoimmunity,
Translation,
Euronext,
Patient,
Biology,
Knowledge,
Vaccine,
Genmab The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.
Key Points:
- The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.
- “Our core mission is to innovate on behalf of patients by translating immunology breakthroughs into novel pipeline candidates.
- “Through our collaboration with Genmab, we are bringing together our combined antibody discovery, development and commercialization expertise to unlock insights on the disease pathways that we will address.
- The collaboration will initially focus on two differentiated targets, including one within immunology and one within cancer, with the potential to expand to more.
Biotechnology,
General Health,
Health,
Science,
Research,
Translation,
Antibody,
Biology,
Knowledge,
Cancer,
Euronext,
Patient,
Inflammation,
Autoimmunity,
Vaccine Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.
Key Points:
- Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.
- The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.
- “Through our collaboration with Genmab, we are bringing together our combined antibody discovery, development and commercialization expertise to unlock insights on the disease pathways that we will address.
- The collaboration will initially focus on two differentiated targets, including one within immunology and one within cancer, with the potential to expand to more.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Conditional sentence,
University,
Leo Pharma,
BV,
Aes,
COVID-19,
American Academy,
Atopic dermatitis,
Development,
Dermatology,
MD,
Patient,
AAD,
LEO,
American Academy of Dermatology,
Cytokine,
Upper respiratory tract infection,
Safety,
Pharmaceutical industry,
EASI LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
Key Points:
- LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
- Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
- LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
- LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.
The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
Key Points:
- The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
- The company’s annual report for the financial year ended December 31, 2022 is now available on its website www.argenx.com/investors/financial-reports.
- The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices.
- argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
Retrieved on:
Wednesday, March 15, 2023
Alfa Romeo,
SMC,
Lancet Neurology,
NICE,
ADAPT,
Healthcare Improvement Scotland,
Euronext,
Patient,
MHRA,
National Institute for Health and Care Excellence,
Acetylcholine receptor,
The Lancet,
Health care,
GMG,
Pharmaceutical industry “We are pleased to announce this latest regulatory approval of VYVGART, another exciting advancement toward our vision of making our innovation available to as many patients as possible," said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
Key Points:
- “We are pleased to announce this latest regulatory approval of VYVGART, another exciting advancement toward our vision of making our innovation available to as many patients as possible," said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
- Responders were defined as having at least a two-point reduction on the MG-ADL scale sustained for four or more consecutive weeks during the first treatment cycle2.
- There were also significantly more responders on the Quantitative Myasthenia Gravis (QMG) scale following treatment with efgartigimod compared with placebo (63% vs. 14%; p
- Responders were defined as having at least a three-point reduction on the QMG scale sustained for four or more consecutive weeks during the first treatment cycle.
Autoimmune disease,
Myasthenia gravis,
National Multiple Sclerosis Society,
Pfizer,
Research,
Roche,
Business,
University,
Neurology,
Ophthalmology,
Neuroscience,
Multiple sclerosis,
Business administration,
Bachelor of Economics,
Marketing,
Economics,
New product development,
Senior,
New York University Stern School of Business,
Euronext,
Master of Business Administration,
Infection,
Pharmaceutical industry,
Management,
Genentech Karen Massey appointed as Chief Operating Officer, effective March 13, 2023
Key Points:
- Karen Massey appointed as Chief Operating Officer, effective March 13, 2023
Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey will join argenx as Chief Operating Officer, effective March 13, 2023.
- Ms. Massey will succeed Keith Woods, who will remain at argenx for a transition period to support the launch of subcutaneous efgartigimod, after which he will retire and serve as a strategic advisor on the Commercial Committee of the argenx Board of Directors.
- “Karen brings extensive commercial launch and leadership experience to argenx, specifically within neurology and autoimmune disease.
- Karen has a genuine passion for innovation and an ability to inspire large, diverse and global teams to deliver results by creating a sense of shared purpose and community,” commented Tim Van Hauwermeiren, Chief Executive Officer at argenx.
GMG,
SC,
FDA,
Research,
Public expenditure,
Leo Pharma,
Sale,
Marketing,
Therapy,
SIMPLE,
Income tax,
Webcast,
Janssen,
BLA,
Video game,
Cryptocurrency,
Pharmaceutical industry,
Life insurance,
EU Collaboration revenue for the fourth quarter and year-to-date in 2022 was $0.8 million and $10 million, respectively, compared to $26 million and $497.3 million for the same periods in 2021.
Key Points:
- Collaboration revenue for the fourth quarter and year-to-date in 2022 was $0.8 million and $10 million, respectively, compared to $26 million and $497.3 million for the same periods in 2021.
- Other operating income for the fourth quarter and year-to-date in 2022 was $7.9 million, and $34.5 million, respectively, compared to $7.7 million and $42.1 million for the same periods in 2021.
- Loss from investment in joint venture for the fourth quarter and year-to-date in 2022 was $0.7 million.
- The full year 2022 results and fourth quarter business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET.
Retrieved on:
Monday, February 27, 2023
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors.
Key Points:
- Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors.
- As a result of the appointment of Mr. Krognes, Werner Lanthaler has formally resigned as non-executive director of the Board of Directors and chairperson of the Audit and Compliance Committee to enable this important step in long-term succession planning.
- “We welcome Steve to the Board and are confident that with his strong financial and compliance expertise and valuable industry knowledge, he possesses the ideal profile to support argenx on our innovative, entrepreneurial mission,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
- “I would also like to express my gratitude to Werner for his substantial contributions over the last eight years.
Retrieved on:
Monday, February 27, 2023
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March:
Key Points:
- Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in March:
Cowen 43rd Annual Healthcare Conference.
- Fireside chat on Monday, March 6, 2023 at 10:30 a.m.
- Raymond James 44th Annual Institutional Investors Conference.
- Presentation on Tuesday, March 7, 2023 at 1:05 p.m.
